近日，香港中文大学于君等研究人员合作发现，一种基于血液的生物标志物组合可用于非侵入性诊断代谢功能障碍相关性脂肪性肝炎。相关论文于2024年11月4日在线发表在《细胞—代谢》杂志上。

研究人员表示，当前代谢功能障碍相关性脂肪性肝病（MASLD）及其严重形式，代谢功能障碍相关性脂肪性肝炎（MASH）的诊断效果不理想。

研究人员招募了700名个体，其中184名来自香港作为发现队列，516名来自圣地亚哥、温州和香港作为三组验证队列。

研究人员制定了一个由三个参数（C-X-C基序趋化因子配体10 [CXCL10]，细胞角蛋白18片段M30 [CK-18]，和调整后的体质指数 [BMI]）组成的组合（命名为N3-MASH），其在区分MASLD患者与健康对照者方面的受试者工作特征曲线下面积（AUROC）为0.954。

在MASLD患者中，N3-MASH可以识别MASH患者，其AUROC为0.823，特异性为90.0%，灵敏度为62.9%，阳性预测值为88.6%。N3-MASH的诊断性能在三个验证队列中的AUROC分别为0.802、0.805和0.823。此外，N3-MASH还能够识别MASH改善患者，其AUROC为0.857。

总之，研究人员开发了一个强大的基于血液的组合，可用于非侵入性诊断MASH，这可能帮助临床医生减少不必要的肝脏活检。

附：英文原文

Title: A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis

Author: Xiang Zhang, Ming-Hua Zheng, Dehua Liu, Yufeng Lin, Sherlot Juan Song, Eagle Siu-Hong Chu, Dabin Liu, Seema Singh, Michael Berman, Harry Cheuk-Hay Lau, Hongyan Gou, Grace Lai-Hung Wong, Ni Zhang, Hai-Yang Yuan, Rohit Loomba, Vincent Wai-Sun Wong, Jun Yu

Issue&Volume: 2024-11-04

Abstract: The current diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe form, metabolic dysfunction-associated steatohepatitis (MASH), is suboptimal. Here, we recruited 700 individuals, including 184 from Hong Kong as a discovery cohort and 516 from San Diego, Wenzhou, and Hong Kong as three validation cohorts. A panel of 3 parameters (C-X-C motif chemokine ligand 10 [CXCL10], cytokeratin 18 fragments M30 [CK-18], and adjusted body mass index [BMI]) was formulated (termed N3-MASH), which discriminated patients with MASLD from healthy controls with an area under the receiver operating characteristic (AUROC) of 0.954. Among patients with MASLD, N3-MASH could identify patients with MASH with an AUROC of 0.823, achieving 90.0% specificity, 62.9% sensitivity, and 88.6% positive predictive value. The diagnostic performance of N3-MASH was confirmed in three validation cohorts with AUROC of 0.802, 0.805, and 0.823, respectively. Additionally, N3-MASH identifies patients with MASH improvement with an AUROC of 0.857. In summary, we developed a robust blood-based panel for the non-invasive diagnosis of MASH, which might help clinicians reduce unnecessary liver biopsies.

DOI: 10.1016/j.cmet.2024.10.008

Source: https://www.cell.com/cell-metabolism/abstract/S1550-4131(24)00404-2